Webinar

#Automated workflows #Automation #Drug discovery #Orchestration #Thermo Fisher Scientific #Webinar

The orchestrated lab: Moving beyond siloed automation

Many laboratories have invested in automation, yet workflows often remain fragmented, with disconnected instruments, data, and processes creating inefficiencies and limiting scalability. As scientific workflows grow more complex, automation alone is no longer enough. Leading labs are now embracing orchestration, the coordination of instruments, robotics, software, data, and people across the… Read More

Webinar date:
Supported by Thermo Fisher Scientific
#Webinars

Cancer tumour
#Champions Oncology #Drug discovery #KRAS #Oncology #Patient-derived tumour models #Tumour models #Webinar

Cracking sensitivity and resistance to Pan-RAS(ON) inhibition with KRAS

KRAS mutations are among the most prevalent oncogenic drivers in solid tumours, yet predicting which patients will respond to targeted therapy — and understanding why resistance inevitably emerges — remains one of the central challenges in oncology drug development. ‘Cracking KRAS: Decoding Sensitivity and Resistance to Pan-RAS(ON) Inhibition Across Patient-Derived… Read More

#News

#Champions Oncology #Drug discovery #KRAS #Oncology #Patient-derived tumour models #Tumour models #Webinar

Webinar: Decoding sensitivity and resistance to Pan-RAS(ON) inhibition

KRAS mutations are among the most prevalent oncogenic drivers in solid tumours, yet predicting which patients will respond to targeted therapy — and understanding why resistance inevitably emerges — remains one of the central challenges in oncology drug development. ‘Cracking KRAS: Decoding Sensitivity and Resistance to Pan-RAS(ON) Inhibition Across Patient-Derived… Read More

#News

#Drug discovery #Fragment-based drug discovery #Hit to lead #Webinar

Accelerating hit discovery for hard-to-target proteins: A fragment library approach applied to MyD88

Fragment-based drug discovery (FBDD) offers an efficient route to explore chemical space, but critical bottlenecks remain. Commercial fragment libraries are either too large to screen routinely with biophysical methods or too small to capture sufficient chemical diversity for challenging targets. Moreover, fragment expansions into focused compound collections lacks streamlined, integrated… Read More

Webinar date:
Supported by BioDuro and ChemPass
#Webinars

#Champions Oncology #Drug discovery #KRAS #Oncology #Patient-derived tumour models #Tumour models #Webinar

Cracking KRAS: Decoding Sensitivity and Resistance to Pan-RAS(ON) Inhibition Across Patient-Derived Tumour Models

KRAS mutations are among the most prevalent oncogenic drivers in solid tumours, yet predicting which patients will respond to targeted therapy — and understanding why resistance inevitably emerges — remains one of the central challenges in oncology drug development. ‘Cracking KRAS: Decoding Sensitivity and Resistance to Pan-RAS(ON) Inhibition Across Patient-Derived… Read More

Webinar date:
Supported by Champions Oncology
#Webinars

#Drug discovery #Fragment-based drug discovery #Webinar

Webinar: Accelerating hit discovery for hard-to-target proteins

Fragment-based drug discovery (FBDD) offers an efficient route to explore chemical space, but critical bottlenecks remain. Commercial fragment libraries are either too large to screen routinely with biophysical methods or too small to capture sufficient chemical diversity for challenging targets. Moreover, fragment expansions into focused compound collections lacks streamlined, integrated… Read More

#News

Antibodies
#Artificial intelligence (AI) #Biologics #Drug discovery #Therapeutic Antibodies #Webinar

Webinar: Meet the challenges of a shifting antibody discovery landscape

Antibody discovery is being reshaped by two forces: an explosion of novel formats and the growing role of AI across the DBTL loop. But most teams are still running antibody programs on software that hasn’t kept pace with science, leaving data siloed and relationships missing. In this webinar, hosted by… Read More

Webinar date:
Supported by Benching
#News

Illustration of a virus
#Biosafety testing #Drug discovery #Next generation sequencing #Webinar

Watch now: Overcome the bottlenecks in AVA testing

Biopharmaceutical manufacturers are under increasing pressure to deliver safe, reliable products at speed – yet adventitious viral agent (AVA) testing remains one of the most significant bottlenecks in the quality control process. In this on-demand webinar, ViruSure, a global leader in pathogen safety testing, shares how it… Read More

Webinar date:
Supported by Oxford Nanopore Technologies and ViruSure
#News

#Drug discovery #Surface plasmon resonance #Webinar

Watch on-demand: Scale your drug discovery programme by 12x

Surface plasmon resonance (SPR) has long been the gold standard for characterising molecular interactions in drug discovery, but throughput limitations have historically constrained its use in early-stage screening campaigns where large numbers of compounds or biologics candidates require rapid triage. The Carterra Vega changes that equation. … Read More

Webinar date:
Supported by Carterra
#News

#Biosafety testing #Drug discovery #Next generation sequencing #Webinar

Watch now: The first GMP-validated AVA test using Oxford Nanopore sequencing

Biopharmaceutical manufacturers are under increasing pressure to deliver safe, reliable products at speed – yet adventitious viral agent (AVA) testing remains one of the most significant bottlenecks in the quality control process. In this on-demand webinar, ViruSure, a global leader in pathogen safety testing, shares how it… Read More

Webinar date:
Supported by Oxford Nanopore Technologies and ViruSure
#News

#Biosafety testing #Drug discovery #Next generation sequencing #Webinar

How ViruSure implemented an NGS-based AVA assay with enhanced sensitivity and specificity

Biopharmaceutical manufacturers are under increasing pressure to deliver safe, reliable products at speed – yet adventitious viral agent (AVA) testing remains one of the most significant bottlenecks in the quality control process. Traditional AVA workflows require numerous parallel and sequential assays, often taking weeks to complete and contributing… Read More

Webinar date:
Supported by Oxford Nanopore Technologies and ViruSure
#Webinars

Antibodies
#Artificial intelligence (AI) #Biologics #Drug discovery #Therapeutic Antibodies #Webinar

Webinar: Discover a modern data foundation for complex biologics

Antibody discovery is being reshaped by two forces: an explosion of novel formats and the growing role of AI across the DBTL loop. But most teams are still running antibody programs on software that hasn’t kept pace with science, leaving data siloed and relationships missing. In… Read More

Webinar date:
Supported by Benching
#News

Peptides
#Artificial intelligence (AI) #Drug discovery #Peptides #Webinar

Last chance to register: Discover cyclic peptide drug design

Cyclic peptides have a special power in the therapeutic space — they’re larger and more specific than small molecules, and more permeable and cost-effective than antibodies. These qualities enable them to conquer two of the biggest challenges in modern drug development: prosecuting flat intracellular protein-protein interactions (PPIs) and achieving oral… Read More

Webinar date:
Supported by BioDuro
#News

#Drug discovery #Surface plasmon resonance #Webinar

Watch now: Efficient data processing and decision-making across large data sets

Surface plasmon resonance (SPR) has long been the gold standard for characterising molecular interactions in drug discovery, but throughput limitations have historically constrained its use in early-stage screening campaigns where large numbers of compounds or biologics candidates require rapid triage. The Carterra Vega changes that equation. … Read More

Webinar date:
Supported by Carterra
#News

Monoclonal antibody
#Artificial intelligence (AI) #Biologics #Drug discovery #Therapeutic Antibodies #Webinar

Webinar: Discover AI infrastructure for modern antibody discovery

Antibody discovery is being reshaped by two forces: an explosion of novel formats and the growing role of AI across the DBTL loop. But most teams are still running antibody programmes on software that hasn’t kept pace with science, leaving data siloed and relationships missing. In this webinar on 11… Read More

Webinar date:
Supported by Benching
#News

Peptide
#Artificial intelligence (AI) #Drug discovery #Peptides #Webinar

Register now: A deep dive into the cyclic peptide discovery landscape

Cyclic peptides have a special power in the therapeutic space — they’re larger and more specific than small molecules, and more permeable and cost-effective than antibodies. These qualities enable them to conquer two of the biggest challenges in modern drug development: prosecuting flat intracellular protein-protein interactions (PPIs) and achieving oral… Read More

Webinar date:
Supported by BioDuro
#News